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Table 3. The Minimum Detectable ORs for Our Analysis under the Log-Additive
Model with Power 80% and a Significance Level of 5%
Comparison
Minimum Detectable OR
RHOB SNP
rs585017
TXNDC3 SNP
rs4720262
All case patients vs. all control subjects 1.23 1.30
Female case patients vs. female control subjects 1.34 1.42
Male case patients vs. male control subjects 1.36 1.45
All knees vs. all control subjects 1.35 1.43
Female knees vs. female control subjects 1.49 1.62
Male knees vs. male control subjects 1.54 1.68
All hips vs. all control subjects 1.25 1.31
Female hips vs. female control subjects 1.36 1.47
Male hips vs. male control subjects 1.38 1.49
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/ (for
rs585017 and rs4720262)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for osteoarthritis, RHOB, and TXNDC3)
Quanto, http://hydra.usc.edu/gxe (for power calculations)
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Reply to Loughlin et al.
To the Editor:
We very much appreciate the effort Loughlin and col-
leagues1 took in trying to replicate our finding of an as-
sociation between osteoarthritis (MIM 165720) and the
RHOB (MIM 165370) SNP rs585017 and the TXNDC3
(MIM 607421) SNP rs4720262.
In our study,2 odds ratios (ORs) of 2.1 and 2.3 describe
the association between osteoarthritis and the RHOB and
TXNDC3 SNPs, respectively, and we had 80% power to
detect ORs as small as 1.6 and 1.8, respectively. Both SNPs
were in Hardy-Weinberg equilibrium in the control group,
so we can confidently rule out obvious methodological
flaws.
Loughlin et al.1 used the same disease ascertainment
that we did (joint replacement of the hip and/or knee),
and they too analyzed Europeans of white ethnicity. Why
then did the study fail? And, by extension, why did all
the previous genomewide scans—no matter how com-
parable the strategies to elucidate the genetics of osteo-
arthritis3,4—not culminate in a coherent set of results?
Obviously, one can always call for an even higher sta-
tistical power or claim that reported associations are spu-
rious. But let us refocus on the disease at hand; osteoar-
thritis is a complex disease, and if there was a simple
genetic pattern involved, surely we would have identified
it by now.5 Assuming that the osteoarthritis pathogenesis
requires a delicate interplay between individual genetic
polymorphisms and regional environmental changes, we
need to question the comparability of a British study and
an eastern German study for disease-associated genes. Ad-
ditionally, we need to identify the strata that reflect the
different etiologies. In fact, table 3 in the letter by Lough-
lin et al.1 might also suggest that increased ORs cannot be
excluded for the strata “osteoarthritis of the knee.” Our
own data support a recessive model for RHOB and a dom-
inant model for TXNDC3. The combination of both risk
factors yields an OR 19; however, our sample numbers are
small. To facilitate testing our hypothesis in the U.K. co-
hort, we emphasize the suggestion that all tested data be
reported as online supplements in their original forms.5
Loughlin et al.1 also raise the issue of the different fre-
quencies for the TXNDC3 SNP rs4720262 in the control
subjects—13.4% in our cohort and 28.8% in the U.K. co-
hort. Indeed, the Ensembl Genome Browser reports a high
variability for this particular SNP, with 2.2% in African
Americans as the lowest. Among Americans of European
descent, the frequencies vary from 21.7% (in HapMap,
among 60 individuals) to 31.2% (in PERLEGEN, among
25 individuals). This points to an elevated variability in
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whites, since these particular PERLEGEN and HapMap co-
horts are not independent of each other (Coriell Institute
for Medical Research, Ensembl Genome Browser, and
HapMap).
Indeed, the frequency of 13.4% in our white control
subjects is striking. However, there is a precedent of dif-
ferent SNP frequencies in British and German popula-
tions,6 which calls for detailed investigations of individual
European populations—down to the haplotype level. We
will certainly perform further analyses to increase the un-
derstanding of our control population. It is also important,
in this context, to specify the origin of all individuals ge-
notyped; in the study of Loughlin et al.,1 268 of the pa-
tients are not mentioned in the reference cited. The sit-
uation for RHOB SNP rs585017 is different; the recessive
effect of the GG genotype is reflected by a frequency of
4.9% in our control subjects and 20.5% in our case pa-
tients. Loughlin et al. found a comparable frequency in
control subjects (6.8%; ), but the frequency in casePp .4
patients was much different (8.3%; ), which6Pp 3# 10
illustrates the points we discussed above.
We are confident that the future of osteoarthritis ge-
netics will encompass both (i) the analysis of even larger
cohorts, with sample cohorts crossing regional bound-
aries—either genetic or environmental—and thus the pos-
sible dilution of effects, and (ii) strategies for zooming in
on regional effects and for designing smart experiments
to test individual traits.
SANDRA MAHR, HOLGER KIRSTEN, AND BRIGITTE MU¨LLER
Web Resources
The URLs for data presented herein are as follows:
Coriell Institute for Medical Research, http://www.coriell.org/
Ensembl Genome Browser, http://www.ensembl.org/
HapMap, http://www.hapmap.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for OH, RHOB, and TXNDC3)
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